The recombinant Bovine Growth Hormone(rBGH), a genetically engineered hormone manufactured by Monsanto, has sparked a controversy nationwide since its introduction to the marketplace a couple of years ago. Sometimes referred to as Bovine Somatotropin (rBST), the bioengineered hormone is injected in the cows every other week to force the cows to produce more milk than their bodies normally would. rBGH is similar, although not identical, to a hormone that the cow naturally produces. Increasing levels of this hormone boosts milk production, causing a number of problems with the milk, among them, raising levels of pus, antibiotics residues and a cancer-accelerating hormone called IGF-1.
"Cows injected with POSILAC are at an increased risk for clinical mastitis (visibly abnormal milk). The number of cows affected with clinical mastitis and the number of cases per cow may increase.... In some herds, use of POSILAC has been associated with increases in somatic cell counts [pus & bacteria]."The warning label goes on to say:
"...use of POSILAC may result in an increase in digestive disorders such as indigestion, bloat, and diarrhea.... Studies indicated that cows injected with POSILAC had increased numbers of enlarged hocks and lesions (e.g., lacerations, enlargements, calluses) of the knee...and...of the foot region."
The economic incentives, rather than preventing antibiotics from reaching the consumer, seem to encourage farmers to use antibiotics which they know won’t be tested for.
Cancer is uncontrolled cell division.
Monsanto, Eli Lilly, Upjohn, and American Cyanamid are the four corporations that stood to profit from the $500 Million to be made from worldwide marketing of rBGH. While they all competed to develop rBGH, only Monsanto has continued to develop and market it. The first 3 of these four companies are convicted corporate felons. All 4 of them have a history of chemical plants that explode, toxic waste spills, deadly toxic gas cloud releases, consumer pharmaceutical products that kill people and produce birth defects, conspiracy to fix prices, antitrust violations, predatory and monopolistic practices, and/or failure to inform Federal officials of testing results indicating fatalities connected to their products.